NEWS ANALYSIS | Sept 20, 2026 | Kratom Truth Project
Something is happening to Cat's Claw right now that should look familiar to anyone paying attention to kratom.
Articles are circulating claiming Cat's Claw products contain unlabeled kratom. Social media videos are calling Cat's Claw dangerous and addictive. In states where kratom has been banned or effectively priced out of the market, people who relied on kratom for chronic pain, anxiety, and stress management have turned to Cat's Claw as an alternative. And almost immediately, Cat's Claw became the next target.
This is not a coincidence. It is the same playbook.
This article is written for three audiences: people who are worried that someone they love is addicted to a botanical supplement, people who are being told they are addicted to one, and retailers and wellness professionals who are fielding these questions. All three deserve accurate information.
What Cat's Claw Actually Is
Cat's Claw (Uncaria tomentosa) is a woody vine native to the Amazon rainforest with centuries of documented traditional use in Peruvian medicine. Its active compounds are primarily oxindole alkaloids, quinovic acid glycosides, and tannins. These work through anti-inflammatory, immunomodulatory, and antioxidant pathways.
People use Cat's Claw for chronic inflammation and joint pain, immune support, mood stabilization, stress management, sustained energy and focus, and general wellness. These are real, documented effects. The supplement is not a placebo and it is not a drug.
What it is not is pharmacologically capable of producing physical dependence. Substance dependence requires sustained action on dopaminergic, opioid, or GABA receptor systems, the mechanisms targeted by alcohol, opioids, benzodiazepines, and stimulants. Cat's Claw does not act on any of these systems in any clinically meaningful way. The pharmacological basis for addiction simply does not exist in this compound.
Cat's Claw is not alone in facing this manufactured alarm. Kava, ashwagandha, and kratom itself have all been subjected to identical campaign patterns: alarming social media content, scripted personal testimonials, coordinated news coverage, and regulatory pressure, timed in each case to the botanical demonstrating enough therapeutic value to threaten pharmaceutical revenue streams or established treatment models. Any effective, affordable, unpatentable botanical is a potential target. Cat's Claw is the current one.
Counterfeit Products, Twisted Headlines, and the Brands Getting Caught in the Crossfire
The specific products generating alarm in Utah require more precise framing than the headlines have provided.
Start with the headline itself. "Illegal kratom found in Cat's Claw products" is doing three misleading things simultaneously. It implies the products contain kratom, which they don't. It implies kratom is illegal, which it is not federally and is not in most states. And it buries the actual story: counterfeit supplement products were found to contain pseudoindoxyl and MGM-15, two synthetic compounds that the DEA placed on Schedule I as of August 26, 2026. These compounds are not kratom. They are not Cat's Claw. They are synthetic derivatives that have nothing to do with either botanical and happen to share a pharmacological family with kratom alkaloids. The accurate headline would read something like: "Counterfeit supplements found to contain newly-scheduled synthetic compounds." That is a completely different story.
Utah Poison Control Center director Amberly Johnson directly described the products in question as "counterfeit Cat's Claw products" in her public statements on the incident. Utah agriculture officials stated explicitly in their own press release that "typical cat's claw, a herbal supplement, does not contain the same compounds found in kratom." The state's own agencies drew a clear line between the botanical and the adulterated products.
Multiple legitimate brands are being swept up in this alarm, and Buzzers is the most prominent example. The legitimate Buzzers product, manufactured by Pivot Brands and sold through authorized distributors, is pure Cat's Claw extract. It contains no kratom, no MGM-15, no mitragynine pseudoindoxyl, and none of the scheduled synthetic compounds found in the Utah products. Their products are verified by third-party certificates of analysis and have been confirmed legal for sale by multiple state agriculture departments in states with active kratom restrictions. The products that tested positive in Utah are counterfeit products using the Buzzers brand name. They are not Pivot Brands' actual product. The alarm generated by the counterfeits does not apply to verified products purchased through authorized distributors.
This is a brand counterfeiting story that is being reported as a botanical safety story. Legitimate supplement brands get counterfeited when they become popular enough to be worth copying, exactly as happens in any consumer product category. When counterfeit products cause harm under a brand name, the legitimate manufacturer's products get swept up in the alarm regardless of their actual contents. Multiple Cat's Claw brands are now facing that same dynamic, their legitimate products associated with incidents caused by knockoffs they did not make.
The American Kratom Association issued a statement calling the Utah products "falsely characterized" as kratom, noting that the synthetic compounds found are not traditional kratom leaf products. Utah's own poison control director called them counterfeit. The botanical is not the story. The counterfeit supply chain is the story.
The correct response is to buy from verified distributors, require current third-party certificates of analysis for every product on your shelf, and trace your supply chain. It is not to condemn Cat's Claw, kratom, or any botanical category for what counterfeit products containing synthetic opioid compounds did under borrowed brand names.
If You're the Concerned Partner or Family Member
The information environment around botanical supplements has been deliberately flooded with alarming content. Scripted personal testimonials describing addiction and withdrawal appear in coordinated clusters across social media platforms, podcast episodes, and news feeds. The same narrative arc appears repeatedly with nearly identical framing: discovery, escalating use, relationship damage, intervention, recovery. This is not organic public concern. It is a coordinated information campaign targeting botanicals that are effective, affordable, and unpatentable.
When you encounter those stories repeatedly and then observe someone you care about who uses a botanical consistently and seems attached to it, your brain connects the dots. That connection feels like recognition. It is not. It is the predictable outcome of an engineered information environment designed to produce exactly that response.
Here is what you are likely actually observing:
Someone who found something that works. People who find effective relief from chronic stress, inflammation, anxiety, sleep disruption, or low energy tend to use that thing consistently. Consistent use of something that genuinely helps is rational health management. The fact that it happens to be a plant rather than a prescription does not change that.
Frustration when their choice is pathologized. If someone is managing a real condition effectively with a safe supplement and is repeatedly told they are an addict, they will become frustrated and defensive. That frustration is not a symptom of addiction. It is a reasonable human response to being mischaracterized by someone they love, based on information neither of you chose to receive.
The return of symptoms when they stop. More on this below.
If You're the Person Being Accused
Being told you are addicted to something you know is helping you is disorienting and painful. The person saying it is not your enemy. They have been targeted by the same campaign that is targeting the products you use, and they love you enough to be scared. Understanding that does not make their concern correct.
A few things worth knowing:
The nocebo effect is real and it is being deliberately weaponized. The nocebo effect is the pharmacological opposite of placebo. Where placebo produces benefit through positive expectation, nocebo produces harm through negative expectation. Research consistently shows that when people are told a substance will cause withdrawal symptoms upon stopping, they experience those symptoms even when the substance has no physical dependence mechanism. If you stop a botanical while believing, or while being told repeatedly, that you will suffer withdrawal, you are significantly more likely to experience something that feels like withdrawal. The information campaign is deliberately seeding the expectation that produces this experience.
Your lived experience is evidence. If you have used a botanical consistently and stopping it has not produced the shaking, sweating, dangerous anxiety, insomnia, or physiological distress that characterizes genuine withdrawal from alcohol or opioids, that is meaningful data. Stable, functional use without escalating dose, without compulsive behavior, without deteriorating life circumstances, does not meet the clinical definition of Substance Use Disorder under DSM-5 criteria regardless of what a social media video told someone you know.
The clinical criteria matter. DSM-5 Substance Use Disorder requires compulsive use despite significant harm, loss of control, craving, and continued use despite persistent negative social, occupational, or health consequences. Using something that helps you function and choosing to stop when you want to is not a Substance Use Disorder by any diagnostic standard.
The person accusing you is also a victim here. Your frustration belongs directed at the campaign, not at them.
What Actually Happens When You Stop
This is the most important section of this article.
When you stop a botanical that has been providing genuine therapeutic benefit, the benefit stops. If you were using Cat's Claw for chronic inflammation, the inflammation returns. If you were using ashwagandha for stress and cortisol regulation, your stress response returns to its previous baseline. If you were using kava for anxiety, your anxiety returns. These are not withdrawal symptoms. This is your underlying condition in the absence of the thing that was managing it.
The experience of original symptoms returning can feel exactly like withdrawal if you have been primed to interpret it that way, which the disinformation campaign has primed you to do.
There is a second mechanism that explains many reported withdrawal experiences from botanicals and is almost never discussed: nutrient deficiency unmasking.
Magnesium deficiency affects an estimated 50% of Americans and is almost never tested for in routine bloodwork. The symptoms of magnesium deficiency include restless legs, anxiety, sleep disruption, muscle tension, fatigue, and brain fog. Many botanicals provide symptomatic relief for these exact conditions, either directly or through stress reduction that improves absorption and utilization. When someone stops a botanical they were using for anxiety, sleep, and restless legs and those symptoms intensify, the correct question is not "am I addicted" but "was this botanical compensating for an underlying deficiency that still exists?"
Magnesium glycinate is inexpensive, well-tolerated, and broadly beneficial. If you are experiencing symptoms after stopping a botanical, trying 300-400mg of magnesium glycinate before bed for two weeks is a more pharmacologically accurate first step than assuming dependence.
True withdrawal requires receptor rebound from substances that have physically altered receptor sensitivity through sustained action. Alcohol withdrawal causes dangerous neurological events through GABA receptor rebound. Benzodiazepine withdrawal involves the same mechanism and can be fatal. Opioid withdrawal involves mu-opioid receptor rebound. These are serious, physiologically dangerous processes. Stopping a botanical that works through anti-inflammatory or adaptogenic pathways is not in the same category by any pharmacological measure.
The Real Danger: What Happens When the Narrative Succeeds
There is a consequence to the manufactured addiction narrative that is rarely discussed and is the most medically serious part of this story.
When someone is successfully convinced that their botanical supplement use is addiction, the implied solution is treatment. Treatment means the clinical system. The clinical system has a limited toolkit for substance use disorder, and that toolkit is dominated by pharmaceutical interventions.
Someone who presents to a clinician reporting botanical supplement addiction may be offered benzodiazepines for the anxiety they were managing with kava or ashwagandha. Benzodiazepines are genuine Schedule IV controlled substances with documented physical dependence, a withdrawal syndrome that can be directly fatal through seizures, and a dependence rate that dwarfs any botanical. Someone who reports mood and stress concerns may be offered SSRIs with discontinuation syndromes that can persist for months. Someone who reports using a botanical for relaxation and sleep may be offered sedative-hypnotics with documented cognitive effects and significant dependence potential.
The campaign that characterizes safe botanical use as addiction is not routing people away from dependence. It is routing people away from unpatentable botanicals and toward the pharmaceutical system, where the products are patented, the prices are clinical, and the dependence profiles are real.
This is not a hypothetical. It is the predictable outcome of an information environment designed to pathologize safe supplement use and direct concerned people toward a medical system equipped to prescribe pharmaceutical solutions to the problem that was just manufactured for them.
For Retailers and Wellness Professionals
If a customer or patient raises addiction concerns, the following is accurate and defensible:
These botanicals do not produce physical dependence through any documented mechanism that would generate clinically significant withdrawal. The alarm circulating in news coverage and social media is not supported by the peer-reviewed pharmacological literature. Claims of withdrawal are almost always explained by one of three things: the return of the original condition being managed, nocebo effects from negative expectation, or the unmasking of underlying nutrient deficiencies, particularly magnesium, that the botanical was partially compensating for.
The most useful thing you can offer is clarity on those three mechanisms. Suggesting a customer stop the supplement for two weeks while addressing potential nutrient deficiencies and observing what happens is often clarifying. If chronic symptoms return, that confirms the product was working. If they experience no symptoms, that confirms there is no dependence.
Regarding the claims that Cat's Claw products contain unlabeled kratom: the correct response is to verify that every product you carry has a current third-party certificate of analysis from an ISO-accredited laboratory. If it does, that claim does not apply to your products. If it does not, getting one should be your immediate priority regardless of this particular controversy.
What you should not do is validate the addiction framing in order to avoid conflict. It does not serve your customer, it does not serve the person worried about them, and it contributes to a manufactured narrative that is causing real harm to real people.
The Bigger Picture
What is happening to Cat's Claw right now is what happened to kratom before it and what will happen to the next effective, affordable, unpatentable botanical after this one. The template is consistent: identify a botanical with meaningful therapeutic value, particularly one that people are turning to precisely because pharmaceutical options have failed them or priced them out, seed alarming content about addiction and danger, generate enough ambient alarm that concerned family members and healthcare providers begin treating normal supplement use as pathological, and create regulatory or market pressure that removes the natural product from consideration.
The financial incentives behind this pattern do not require a coordinated conspiracy. They require only that pharmaceutical companies understand their market. An effective botanical that gets people off opioids, manages anxiety without benzodiazepines, or stabilizes mood without SSRIs is not a public health solution in a system that profits from ongoing pharmaceutical dependency. It is a revenue threat.
The people most harmed by these campaigns are always the same people: those managing real conditions with limited healthcare access who found something affordable and effective and are now being told by the people they love, based on manufactured alarm, that their health management is addiction.
Understanding what is actually happening is the beginning of refusing to let it work.
The Kratom Truth Project investigates the financial conflicts and coordinated disinformation behind botanical prohibition campaigns. kratomtruthproject.org
